Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double‑blind study of PF-06823859 in active dermatomyositis and polymyositis
jRCT2031230382Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM) and polymyositis (PM) comparing PF-06823859 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Moderate change in Total Improvement Score (primary). Started Oct 2023; status: recruiting.
02
Drugs
dazukibart
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on jRCT2031230382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230382.